查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2158970

Regorafenib藥物市場：全球市場預測，2026-2032年

Regorafenib Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Regorafenib藥物市場將成長至 48.8 億美元，複合年成長率為 13.16%。

主要市場統計數據
基準年 2025 20.5億美元
預計年份：2026年 23.3億美元
預測年份 2032 48.8億美元
複合年成長率 (%) 13.16%

Regorafenib製劑：概述

Regorafenib是一種口服多激酶抑制劑，已獲得當地監管機構的批准，用於治療特定腫瘤領域，包括先前接受過治療的結直腸癌、胃腸道基質腫瘤和肝細胞癌。其臨床應用取決於治療方案的順序、生物標記和疾病狀態的評估、耐受性管理以及獲得專業腫瘤護理的機會。由於適應症和醫保報銷條件因地區而異，治療決策應依據最新的處方資訊和臨床指南制定。

治療路徑正變得越來越系統化和以患者為中心。

Regorafenib的治療模式正在不斷發展，這體現在更嚴格的患者篩選、早期毒性識別和結構化的劑量管理方法。臨床醫師越來越注重在控制疾病的同時，兼顧手足皮膚反應、疲乏、高血壓、腹瀉、肝毒性和其他不利事件的管理。真實世界數據和治療順序的比較研究也支持在結直腸癌、胃腸道基質腫瘤和肝細胞癌的治療中採取更個人化的決策。同時，對於合併多種複雜疾病且有既往治療史的患者，多學科診療仍然至關重要。

人工智慧正在加強證據解讀與醫療照護之間的關聯。

人工智慧 (AI) 可透過識別治療反應模式、從縱向記錄中指出潛在毒性風險以及協助臨床醫生整合影像、實驗室、病理和藥物數據來支持Regorafenib。預測工具可能有助於確定臨床試驗的合格和對患者進行分層，但其價值取決於代表性的資料集、透明的檢驗、隱私保護和臨床監督。人工智慧應作為腫瘤科醫師判斷的補充，而非替代，尤其是在證據有限或各國監管規定存在差異的情況下。

區域洞察：准入、監測和臨床基礎設施的差異

在北美，腫瘤診療網路、電子健康記錄和專業支援服務已基本建立，但保險報銷規則和預先核准要求可能會影響患者獲得治療的機會。在歐洲，先進的癌症醫療體系與各國特有的醫療技術評估和採購流程結合。亞太地區雖然存在先進的腫瘤中心，但在診斷、經濟負擔和遍遠地區的醫療服務可近性方面存在顯著差異。在拉丁美洲，專科護理和藥物的供應情況各不相同，公共和私人醫療體係也會影響治療的連續性。在中東，主要都市區提供先進的腫瘤服務，但轉診途徑和保險覆蓋範圍各不相同。在非洲，癌症診斷、專科醫生資源、藥物採購和毒性監測方面仍存在許多限制，因此加強醫療體系建設尤為重要。

群體特定見解：經濟和政治集團因素影響實施條件

東南亞國協在監管成熟度、癌症治療基礎設施和報銷體系方面存在顯著差異，因此需要製定針對特定國家的准入和宣傳策略。金磚國家擁有龐大且多元化的患者群體，其公共衛生體系、國內生產政策以及承擔治療費用的能力各不相同。歐盟受通用的科學和監管框架影響，但報銷和採購方面的決策權仍保留在各個成員國手中。七國集團（G7）國家通常擁有高度專業化的醫療保健體系和實證機制，但各國的准入途徑在行政層面仍有差異。海灣合作理事會（GCC）國家通常將集中化、高度專業化的醫療保健基礎設施與跨境轉診模式結合。北約成員國的醫療保健市場並不統一，但許多成員國已建立藥物警戒和專業的癌症治療體系，能夠支持實證實踐和安全措施的協調。

國家概況：國家法規和腫瘤醫療保健系統仍然是決定性因素。

澳洲和加拿大依賴專科醫生評估和公共或混合保險報銷途徑，但地域分散影響了治療的連續性。巴西和墨西哥在獲得公立和私立癌症治療方面存在顯著差異，區域採購能力和轉診系統影響治療的可近性。中國和印度在大都會圈擁有先進的癌症中心，但在經濟能力和專科醫生資源方面存在顯著的區域差異。包括日本、韓國和新加坡在內的東協國家，以及法國、德國、義大利、西班牙和英國等歐洲國家，擁有成熟的腫瘤治療體系，但它們的核准流程、指南採納和報銷流程各不相同。俄羅斯的醫療服務取得環境受國內政策、採購和專科醫生分佈的影響。在上述所有國家，監測能力、病患教育和及時處理不利事件對於安全用藥至關重要。

優先考慮患者選擇、毒性管理和循證准入計劃。

行業領導者應根據​​已批准的適應症、當地指南以及腫瘤團隊的實際需求來製定教育計劃。投資應著重於標準化的毒性控制方案、護理師和藥劑師的參與、用藥依從性支持以及快速檢測和臨床追蹤。循證策略應將對照試驗與透明的真實世界數據、亞組分析和患者報告結局相結合。區域規劃應考慮報銷途徑、診斷能力、當地轉診障礙和監管要求，而不是依賴統一的全球模式。只有在確保臨床檢驗、網路安全措施和明確的課責機制後，才能實施數位化和人工智慧驅動的工具。

調查方法：基於證據的臨床和醫療保健系統因素審查。

本執行摘要對Regorafenib治療的背景進行了結構化的定性回顧，重點關注已批准的治療用途、臨床管理注意事項、獲取途徑以及特定地區、群體和國家醫療保健系統的差異。研究結果根據公開檢驗的類別進行組織，包括監管適應症、腫瘤基礎設施、報銷流程、藥物安全監測和已發表的臨床證據。本摘要未使用任何市場估算、預測、市場佔有率、預估或公司特定聲明。在做出實際決策之前，應根據當地現行的監管文件、指南、支付方政策和同行評審的證據對國家和地區層面的解釋檢驗。

結論：安全、有針對性地使用Regorafenib。

Regorafenib仍然是一種特殊的治療選擇，其價值取決於合適的患者選擇、謹慎的治療順序、積極的不利事件管理以及可靠的腫瘤專科診療。由於監管、報銷、基礎設施和監測能力等方面的差異，在推廣應用過程中必須根據不同的醫療環境進行調整。那些能夠將臨床證據與患者支持、透明的安全措施以及本地化的用藥方案相結合的領導者，最有利於在改善治療服務的同時，維持藥物的合理使用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章Regorafenib藥物市場：依適應症分類

  • 結腸癌
  • 胃腸道基質腫瘤
  • 肝細胞癌

第8章Regorafenib藥物市場：依產品類型分類

  • 品牌
  • 非專利的

第9章Regorafenib藥物市場：依劑型分類

  • 膠囊
  • 藥片

第10章：Regorafenib藥物市場：依給藥途徑分類

  • 靜脈
  • 口服

第11章Regorafenib藥物市場：以最終用戶分類

  • 醫院
  • 專科診所
    • 癌症中心
    • 腫瘤診所

第12章Regorafenib藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章Regorafenib藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章Regorafenib藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Accord Healthcare Inc.
  • Alembic Pharmaceuticals Limited
  • Bayer AG
  • Cipla Limited
  • Dev Medical Pvt. Ltd.
  • Dr. Reddy's Laboratories Limited
  • Harisons Life Science Pvt. Ltd.
  • Heet Healthcare Private Limited
  • Intas Pharmaceuticals Limited
  • KK Pharma Solutions Pvt. Ltd.
  • Natco Pharma Limited
  • Prissm Pharma Pvt. Ltd.
  • Privet Pharma Pvt. Ltd.
  • Rutika Lifescience Pvt. Ltd.
  • Sandoz International GmbH
  • Sanskruti Pharma Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Surya Speciality Pharma Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

第17章 主要專家

Product Code: MRR-4654A89DBBE1

The Regorafenib Drugs Market is projected to grow by USD 4.88 billion at a CAGR of 13.16% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.05 billion
Estimated Year [2026] USD 2.33 billion
Forecast Year [2032] USD 4.88 billion
CAGR (%) 13.16%

Regorafenib Drugs: Executive Overview

Regorafenib is an oral multikinase inhibitor used in defined oncology settings, including previously treated colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma, subject to local regulatory labeling. Its clinical role is shaped by treatment-line sequencing, biomarker and disease-status assessment, tolerability management, and access to specialist oncology care. Because indications and reimbursement conditions vary by jurisdiction, treatment decisions require alignment with current prescribing information and clinical guidelines.

Treatment Pathways Are Becoming More Structured and Patient-Centered

The regorafenib treatment landscape is evolving through more deliberate patient selection, earlier toxicity recognition, and structured dose-management approaches. Clinicians increasingly balance disease control against hand-foot skin reaction, fatigue, hypertension, diarrhea, hepatotoxicity, and other adverse events. Real-world evidence and comparative sequencing research are also supporting more individualized decisions across colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma, while multidisciplinary care remains important for patients with complex comorbidities or prior therapies.

Artificial Intelligence Is Strengthening Evidence Interpretation and Care Coordination

Artificial intelligence can support regorafenib care by identifying treatment-response patterns, flagging potential toxicity risks from longitudinal records, and helping clinicians integrate imaging, laboratory, pathology, and medication data. Predictive tools may assist trial matching and patient stratification, but their value depends on representative datasets, transparent validation, privacy safeguards, and clinical oversight. AI should augment-not replace-oncologists' judgment, especially where evidence is limited or regulatory labeling differs across countries.

Regional Insights: Access, Monitoring, and Clinical Infrastructure Differ

North America generally benefits from established oncology networks, electronic health records, and specialized supportive-care services, while reimbursement rules and prior-authorization requirements can affect access. Europe combines sophisticated cancer systems with country-specific health-technology assessment and procurement processes. Asia-Pacific contains advanced oncology centers alongside substantial variation in diagnosis, affordability, and rural access. Latin America faces uneven availability of specialist care and medicines, with national and private systems influencing treatment continuity. In the Middle East, major urban centers may offer advanced oncology services, while referral pathways and coverage vary. Africa continues to face constraints in cancer diagnosis, specialist capacity, medicines procurement, and toxicity monitoring, making health-system strengthening particularly important.

Group Insights: Economic and Political Blocs Shape Implementation Conditions

ASEAN markets differ considerably in regulatory maturity, oncology infrastructure, and reimbursement, creating a need for country-specific access and education strategies. BRICS members span large and diverse patient populations with contrasting public-health capacity, domestic production policies, and treatment affordability. The European Union is influenced by shared scientific and regulatory frameworks but retains national reimbursement and procurement decisions. G7 countries typically have strong specialist-care capacity and evidence-generation systems, although access pathways remain administratively distinct. GCC countries often combine concentrated advanced-care infrastructure with cross-border referral patterns. NATO members are not a uniform healthcare market, but many have established pharmacovigilance and specialist oncology systems that can support coordinated evidence and safety practices.

Country Insights: National Regulation and Oncology Capacity Remain Decisive

Australia and Canada rely on specialist assessment and public or mixed reimbursement pathways, with geographic dispersion affecting continuity of care. Brazil and Mexico show substantial differences between private and public oncology access, while local procurement and referral capacity influence treatment availability. China and India combine advanced metropolitan cancer centers with marked regional variation in affordability and specialist access. Japan, South Korea, Singapore-linked ASEAN pathways, and European countries such as France, Germany, Italy, Spain, and the United Kingdom have mature oncology systems, but approval, guideline adoption, and reimbursement processes differ. Russia's access environment is shaped by domestic policy, procurement, and specialist distribution. Across all listed countries, monitoring capacity, patient education, and timely management of adverse events are central to safe use.

Prioritize Patient Selection, Toxicity Control, and Evidence-Based Access Planning

Industry leaders should align educational programs with approved indications, local guidelines, and the practical needs of oncology teams. Investment should focus on standardized toxicity-management protocols, nurse and pharmacist engagement, adherence support, and rapid laboratory or clinical follow-up. Evidence strategies should combine controlled studies with transparent real-world data, subgroup analyses, and patient-reported outcomes. Regional planning should account for reimbursement pathways, diagnostic capacity, rural referral barriers, and regulatory requirements rather than assuming a uniform global model. Digital and AI-enabled tools should be deployed only with clinical validation, cybersecurity controls, and clear accountability.

Research Methodology: Evidence-Led Review of Clinical and Health-System Factors

This executive summary uses a structured qualitative review of the regorafenib treatment context, emphasizing approved therapeutic use, clinical-management considerations, access conditions, and health-system variation across the specified regions, groups, and countries. Findings are framed around publicly verifiable categories such as regulatory labeling, oncology infrastructure, reimbursement processes, pharmacovigilance, and published clinical evidence. No market estimates, market shares, forecasts, or company-specific claims are used. Country and regional interpretations should be validated against current local regulatory documents, guidelines, payer policies, and peer-reviewed evidence before operational decisions are made.

Conclusion: Safe, Targeted Use Will Define Regorafenib's Ongoing Role

Regorafenib remains a specialized option whose value depends on appropriate patient selection, careful sequencing, proactive adverse-event management, and reliable access to oncology expertise. Differences in regulation, reimbursement, infrastructure, and monitoring capacity mean that implementation must be tailored to each healthcare environment. Leaders who connect clinical evidence with patient support, transparent safety practices, and locally grounded access planning will be best positioned to improve treatment delivery while maintaining appropriate use.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Regorafenib Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Colorectal Cancer
  • 7.3. Gastrointestinal Stromal Tumors
  • 7.4. Hepatocellular Carcinoma

8. Regorafenib Drugs Market, by Product Type

  • 8.1. Introduction
  • 8.2. Branded
  • 8.3. Generic

9. Regorafenib Drugs Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Capsule
  • 9.3. Tablet

10. Regorafenib Drugs Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Intravenous
  • 10.3. Oral

11. Regorafenib Drugs Market, by End User

  • 11.1. Introduction
  • 11.2. Hospitals
  • 11.3. Specialty Clinics
    • 11.3.1. Cancer Centers
    • 11.3.2. Oncology Clinics

12. Regorafenib Drugs Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Regorafenib Drugs Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Regorafenib Drugs Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Accord Healthcare Inc.
  • 16.2. Alembic Pharmaceuticals Limited
  • 16.3. Bayer AG
  • 16.4. Cipla Limited
  • 16.5. Dev Medical Pvt. Ltd.
  • 16.6. Dr. Reddy's Laboratories Limited
  • 16.7. Harisons Life Science Pvt. Ltd.
  • 16.8. Heet Healthcare Private Limited
  • 16.9. Intas Pharmaceuticals Limited
  • 16.10. K. K. Pharma Solutions Pvt. Ltd.
  • 16.11. Natco Pharma Limited
  • 16.12. Prissm Pharma Pvt. Ltd.
  • 16.13. Privet Pharma Pvt. Ltd.
  • 16.14. Rutika Lifescience Pvt. Ltd.
  • 16.15. Sandoz International GmbH
  • 16.16. Sanskruti Pharma Pvt. Ltd.
  • 16.17. Sun Pharmaceutical Industries Limited
  • 16.18. Surya Speciality Pharma Pvt. Ltd.
  • 16.19. Teva Pharmaceutical Industries Ltd.
  • 16.20. Viatris Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Regorafenib Drugs Market, Years Considered for the Study
  • FIGURE 2. Global Regorafenib Drugs Market, Research Design
  • FIGURE 3. Global Regorafenib Drugs Market, Research Framework
  • FIGURE 4. Global Regorafenib Drugs Market, Data Triangulation
  • FIGURE 5. Global Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Regorafenib Drugs Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global Regorafenib Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Regorafenib Drugs Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Regorafenib Drugs Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Regorafenib Drugs Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 11. Global Regorafenib Drugs Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Regorafenib Drugs Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 13. Global Regorafenib Drugs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Regorafenib Drugs Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Regorafenib Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Regorafenib Drugs Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Regorafenib Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Regorafenib Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Regorafenib Drugs Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Regorafenib Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Regorafenib Drugs Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Regorafenib Drugs Market Segmentation & Coverage
  • TABLE 2. Global Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Gastrointestinal Stromal Tumors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Gastrointestinal Stromal Tumors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Gastrointestinal Stromal Tumors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Hepatocellular Carcinoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Hepatocellular Carcinoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Hepatocellular Carcinoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 14. Global Branded Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Branded Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Branded Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 21. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 22. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 23. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 24. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 28. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 35. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Cancer Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Cancer Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Cancer Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Oncology Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Oncology Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Oncology Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Regorafenib Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Asia-Pacific Regorafenib Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Asia-Pacific Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 50. Asia-Pacific Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 51. Asia-Pacific Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 52. Asia-Pacific Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 53. Asia-Pacific Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 54. Asia-Pacific Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 55. North America Regorafenib Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. North America Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 57. North America Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 58. North America Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 59. North America Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 60. North America Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 61. North America Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 62. Latin America Regorafenib Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Latin America Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 64. Latin America Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 65. Latin America Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 66. Latin America Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 67. Latin America Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 68. Latin America Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 69. Europe Regorafenib Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Europe Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 71. Europe Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 72. Europe Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 73. Europe Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 74. Europe Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 75. Europe Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 76. Middle East Regorafenib Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Middle East Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 78. Middle East Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 79. Middle East Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 80. Middle East Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 81. Middle East Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 82. Middle East Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 83. Africa Regorafenib Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Africa Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 85. Africa Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 86. Africa Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 87. Africa Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 88. Africa Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 89. Africa Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 90. Global Regorafenib Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. ASEAN Regorafenib Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. ASEAN Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 93. ASEAN Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 94. ASEAN Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 95. ASEAN Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 96. ASEAN Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 97. ASEAN Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 98. GCC Regorafenib Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 99. GCC Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 100. GCC Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 101. GCC Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 102. GCC Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 103. GCC Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 104. GCC Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 105. European Union Regorafenib Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 106. European Union Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 107. European Union Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 108. European Union Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 109. European Union Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 110. European Union Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 111. European Union Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 112. BRICS Regorafenib Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 113. BRICS Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 114. BRICS Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 115. BRICS Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 116. BRICS Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 117. BRICS Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 118. BRICS Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 119. G7 Regorafenib Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 120. G7 Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 121. G7 Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 122. G7 Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 123. G7 Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 124. G7 Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 125. G7 Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 126. NATO Regorafenib Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 127. NATO Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 128. NATO Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 129. NATO Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 130. NATO Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 131. NATO Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 132. NATO Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 133. Global Regorafenib Drugs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 134. United States Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 135. United States Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 136. United States Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 137. United States Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 138. United States Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 139. United States Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 140. United States Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 141. Canada Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 142. Canada Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 143. Canada Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 144. Canada Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 145. Canada Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 146. Canada Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 147. Canada Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 148. Mexico Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 149. Mexico Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 150. Mexico Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 151. Mexico Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 152. Mexico Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 153. Mexico Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 154. Mexico Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 155. Brazil Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 156. Brazil Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 157. Brazil Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 158. Brazil Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 159. Brazil Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 160. Brazil Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 161. Brazil Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 162. United Kingdom Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 163. United Kingdom Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 164. United Kingdom Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 165. United Kingdom Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 166. United Kingdom Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 167. United Kingdom Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 168. United Kingdom Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 169. Germany Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 170. Germany Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 171. Germany Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 172. Germany Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 173. Germany Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 174. Germany Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 175. Germany Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 176. France Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 177. France Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 178. France Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 179. France Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 180. France Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 181. France Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 182. France Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 183. Russia Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 184. Russia Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 185. Russia Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 186. Russia Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 187. Russia Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 188. Russia Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 189. Russia Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 190. Italy Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 191. Italy Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 192. Italy Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 193. Italy Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 194. Italy Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 195. Italy Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 196. Italy Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 197. Spain Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 198. Spain Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 199. Spain Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 200. Spain Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 201. Spain Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 202. Spain Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 203. Spain Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 204. China Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 205. China Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 206. China Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 207. China Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 208. China Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 209. China Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 210. China Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 211. India Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 212. India Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 213. India Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 214. India Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 215. India Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 216. India Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 217. India Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 218. Japan Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 219. Japan Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 220. Japan Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 221. Japan Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 222. Japan Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 223. Japan Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 224. Japan Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 225. Australia Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 226. Australia Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 227. Australia Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 228. Australia Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 229. Australia Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 230. Australia Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 231. Australia Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 232. South Korea Regorafenib Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 233. South Korea Regorafenib Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 234. South Korea Regorafenib Drugs Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 235. South Korea Regorafenib Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 236. South Korea Regorafenib Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 237. South Korea Regorafenib Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 238. South Korea Regorafenib Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 239. Global Regorafenib Drugs Market Share, by Key Player, 2025
  • TABLE 240. Global Regorafenib Drugs Market, Key Experts